Prelude Therapeutics director granted 38,000 stock options

Prelude Therapeutics Inc director Sandor Victor received a grant of stock options covering 38,000 shares of common stock.

Rhea-AI Filing Summary

Prelude Therapeutics Inc director Sandor Victor received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.

The award will fully vest upon the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Victor continues providing service through the applicable vesting date. After this grant, he holds options for 38,000 shares directly.

Insider Trade Summary

Grant/Award: 38,000 shares

Grant/Award 1 txn

Insider Sandor Victor

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	38,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 38,000 contracts (Direct)

Footnotes (1)

1. F1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Option grant size: 38,000 options Exercise price: $3.94 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 38,000 options Director stock option grant covering common shares

Exercise price $3.94 per share Strike price for director stock options

Expiration date June 8, 2036 Option term end for director grant

Underlying shares 38,000 shares Common stock underlying the options

Holdings after transaction 38,000 options Total options held following this grant

Key Terms

Director Stock Option (Right to Buy), grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price of 3.9400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual stockholder meeting financial

"vest upon the earlier of the Issuer's next annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prelude Therapeutics (PRLD) director Sandor Victor report in this Form 4?

Director Sandor Victor reported receiving a grant of stock options for 38,000 shares of Prelude Therapeutics common stock. These are compensation-related options, not an open-market purchase, and give him the right to buy shares at a preset exercise price.

How many Prelude Therapeutics (PRLD) shares are covered by Sandor Victor’s new options?

The option grant covers 38,000 shares of Prelude Therapeutics common stock. These options give him the right to acquire that number of shares in the future, subject to vesting conditions and payment of the stated exercise price per share.

What is the exercise price of Sandor Victor’s Prelude Therapeutics (PRLD) stock options?

The options have an exercise price of $3.94 per share. This is the fixed price at which he can buy Prelude Therapeutics common stock once the options vest, regardless of the market price at that time.

When do Sandor Victor’s Prelude Therapeutics (PRLD) options vest?

The options will fully vest on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date. Vesting requires that he continue providing service to Prelude Therapeutics through the applicable vesting date.

When do Sandor Victor’s Prelude Therapeutics (PRLD) stock options expire?

The stock options expire on June 8, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to buy Prelude Therapeutics common stock at the $3.94 per-share exercise price.

Is Sandor Victor buying or selling Prelude Therapeutics (PRLD) shares in this Form 4?

He is not buying or selling shares on the open market. The Form 4 reports a grant of stock options as compensation, classified as an acquisition of a derivative security rather than a purchase or sale of existing Prelude Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandor Victor

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3.94	06/09/2026		A		38,000		(1)	06/08/2036	Common Stock	38,000	$0.00	38,000	D

Explanation of Responses:

1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Krishna Vaddi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)